(Reuters) – A federal advisory committee will put off vote on recommending who should get initial limited doses of a potential COVID-19 vaccine, until members learn more about the vaccines that could become available first, the Wall Street Journal reported on Tuesday, citing people familiar the matter.
The Advisory Committee on Immunization Practices, a group of external medical experts that advises the Centers for Disease Control and Prevention, was expected to vote on Tuesday on a plan to prioritize initial doses of any vaccine that proves safe and effective in clinical trials. https://bit.ly/2FUqi5s
The committee may wait until government officials authorize a specific vaccine or vaccines for use before voting on how to give priority to initial doses, according to the report https://www.wsj.com/articles/cdc-advisory-panel-to-delay-vote-on-initial-covid-19-vaccine-roll-out-11600772401?mod=searchresults&page=1&pos=2.
There is no approved vaccine for the respiratory illness caused by the novel coronavirus and companies such as Pfizer Inc, AstraZeneca Plc and Moderna Inc have vaccine candidates in late-stage clinical testing.
CDC did not immediately respond to a Reuters request for comment.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil D’Silva)
